Search
                    Carboplatin Treatment Options in Minnesota
A collection of 350 research studies where Carboplatin is the interventional treatment. These studies are located in the Minnesota, United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
            313 - 324 of 350
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
                                
            
            
        Completed
                            
            
                The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/18/2014
            
            Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis Park, Minnesota         
        
        
            Conditions: Head and Neck Neoplasms
        
            
        
    
                
                                    Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors.             
        
        
    Gender:
                ALL
            Ages:
                2 years and below
            Trial Updated:
                03/27/2014
            
            Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota  +3 locations         
        
        
            Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
        
            
        
    
                
                                    Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
                                
            
            
        Completed
                            
            
                RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as carboplatin and lobradimil may make the tumor cells more sensitive to radiation therapy.
PURPOSE: Phase I trial to study the effectiveness of combining radiation therapy with carboplatin and lobradimil in treating children who have newly diagnosed brain stem gliomas.             
        
        
    Gender:
                ALL
            Ages:
                Between 3 years and 21 years
            Trial Updated:
                02/19/2014
            
            Locations: Mayo Clinic Cancer Center, Rochester, Minnesota         
        
        
            Conditions: Brain and Central Nervous System Tumors
        
            
        
    
                
                                    Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin works in treating patients with recurren...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                02/12/2014
            
            Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota  +2 locations         
        
        
            Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
        
            
        
    
                
                                    Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vinblastine when given together with carboplatin in treating young patients with newly diagnosed or recurrent low-grade glioma.             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                02/11/2014
            
            Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota         
        
        
            Conditions: Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
        
            
        
    
                
                                    Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed.
PURPOSE: This phase III trial is studying how well giving combination chemotherapy with or with...  Read More             
        
        
    Gender:
                ALL
            Ages:
                10 years and below
            Trial Updated:
                12/17/2013
            
            Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota         
        
        
            Conditions: Brain and Central Nervous System Tumors
        
            
        
    
                
                                    Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
                                
            
            
        Terminated
                            
            
                Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/11/2013
            
            Locations: Pfizer Investigational Site, St. Louis Park, Minnesota         
        
        
            Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
                                
            
            
        Completed
                            
            
                To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/12/2013
            
            Locations: Not set, Rochester, Minnesota         
        
        
            Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer
        
            
        
    
                
                                    Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritonea...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                11/05/2013
            
            Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota         
        
        
            Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
        
            
        
    
                
                                    Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
                                
            
            
        Completed
                            
            
                This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to gr...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                10/25/2013
            
            Locations: North Central Cancer Treatment Group, Rochester, Minnesota         
        
        
            Conditions: Recurrent Melanoma, Stage IV Melanoma
        
            
        
    
                
                                    Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
                                
            
            
        Completed
                            
            
                Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib.
Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                10/01/2013
            
            Locations: Pfizer Investigational Site, Rochester, Minnesota         
        
        
            Conditions: Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
                                
            
            
        Completed
                            
            
                The goal of this study was to determine the effect on overall survival and progression free survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative).
Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the poly (A...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                09/13/2013
            
            Locations: Research Site, Minneapolis, Minnesota  +1 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    313 - 324 of 350
            